This survey is conducted to investigate safety and efficacy under the post marketed drug utilization on the patient with rheumatoid arthritis (only for patients with an inadequate response to prior conventional therapy) at the time of switching regimen from 10 mg twice a week administration to 25 mg once a week administration.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01230177?cond=%22Arthritis%22&lup_s=07/28/2011&lup_d=30
